PROKARIUM
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Livija Deban, PhD, as Chief Scientific Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102005305/en/
“Since joining Prokarium, Livija has been central to the strategic and operational development of the company’s immuno-oncology portfolio, including our next-generation Salmonella platform,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “I look forward to closely working with her and the team to establish Prokarium as a recognized leader in microbial immunotherapy.”
“At Prokarium, we are leveraging cutting edge science at the intersection of immunology and synthetic biology to develop innovative therapies for the treatment of solid tumors,” said Dr. Deban. “Our approach builds on the long history of microbial immunotherapy and holds the promise of providing solutions to many clinical needs that cannot be addressed by current cancer therapeutics. I am honored to be appointed as CSO and am excited to work with the leadership team and the board to accelerate our pipeline.”
Dr. Deban previously served as Prokarium’s Vice President of Research. Prior to joining Prokarium, she led the immuno-oncology R&D at Oxford BioTherapeutics, where she focused on the target discovery and the development of antibodies for cancer treatment. Previously, Dr. Deban conducted her postdoctoral academic research at Cancer Research UK and King’s College London. She received her master’s degree in Medical Biotechnology from the University of Bologna and holds a PhD in Basic and Applied Immunology from University Vita-Salute San Raffaele, Italy.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK. For further information, visit https://www.prokarium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005305/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace Signs MoU with Ethiopian Company to Address Social Challenges through the Utilization of Satellite Data15.1.2026 07:30:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” has made a Memorandum of Understanding (MoU) with Jethi Software Development PLC (“Jethi”), an Ethiopian technology company, to cooperate on addressing social and development challenges through the utilization of satellite-based Earth observation (EO) data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114413353/en/ Naol Debele, Chief Executive Officer of Jethi (left), and Yuya Nakamura, President and CEO of Axelspace, at the signing ceremony on January 13 in Ethiopia The MoU was signed by Naol Debele, Chief Executive Officer of Jethi, and Yuya Nakamura, President and CEO of Axelspace. The signing ceremony, held in Ethiopia on January 13 (local time), was attended by representatives of the Space Science and Geospatial Institute (SSGI) of Ethiopia, members of the Jethi Bo
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom